Epalinges, Switzerland/Los Angeles, USA – September 19, 2024 – In a groundbreaking partnership aimed at improving women’s health, ASPIVIX, a leading innovator in gynecological and fertility solutions, and Tia women’s health clinics, the modern medical home for women, are redefining the way women experience gynecological care across the United States.

Together, ASPIVIX and Tia will expand access to enhanced IUD procedures and improve experience for women in 9 Tia clinics in Los Angeles, New York, San Francisco and Scottsdale across 3 states. The two healthcare trailblazers share the same mission: to put women first by delivering the care each woman needs and deserves through a people-centered approach. This partnership represents a critical step in that mission, setting new standards in the field of gynecology.
This collaboration will provide comprehensive care and improve patient experiences by offering Carevix™, the advanced, pain-reducing solution for women undergoing IUD insertions, for the first time in the US.

This partnership marks ASPIVIX’s further expansion into the U.S. market, following FDA approval of Carevix™ and positive clinical data presented at ACOG 2024.
Moving away from the use of the traumatic cervical tenaculum, Carevix™ is designed to redefine the standards of care in gynecology, offering a more comfortable and empowering experience for patients and healthcare providers alike for transcervical procedures in gynecology.

“At Tia, we prioritize listening to women and addressing their needs. We know that IUD insertions can be a painful experience, and we’ve heard women’s frustrations about their pain being dismissed or minimized. That’s why we’re excited to partner with ASPIVIX as part of their Ambassador Program to offer Carevix™, a breakthrough device that reduces pain during IUD insertions. By integrating Carevix™ alongside our existing pain management options, we are committed to providing a more comfortable and compassionate experience for our patients.” said Devon Klauck, WHNP, Senior Director, Clinical Product at Tia.

“With the CDC urging physicians to better manage pain during IUD procedures, our partnership with Tia represents a victory for women advocating for better care. It’s an important step for ASPIVIX as we continue to align our patient-centric solution,” shares Ikram Guerd, General Manager US of ASPIVIX. “Tia joins University hospitals already using Carevix™, IU Health School of Medicine and Columbia University, allowing ASPIVIX to expand our reach in the US market with the right partners advancing women’s health and making significant advancements in gynecological care.“

Tia health clinics join the centers of excellence with dedicated healthcare providers using Carevix™ in routine gynecological procedures to provide a better experience for women.
Over 700 patients globally have experienced enhanced care with Carevix™, with over 90% reporting satisfaction for IUD and other transcervical procedures (hysteroscopy, endocervical biopsies…). Women undergoing IUD placement at Tia will now experience a more comfortable and less painful procedure with Carevix™ solution transforming their gynecological care experience.

Now, ASPIVIX is excited about expanding the access to Carevix™ to healthcare professionals to improve patient outcomes by redefining together the standard of care in clinical practice.
Carevix™ will be available across 9 clinics (Los Angeles: Studio City, Culver City, Silver Lake, Pasadena, Santa Monica, San Francisco, New York Soho & Williamsburg, Scottsdale) by the end of September 2024.
As Carevix™ continues to lead the charge in clinical settings, we invite more clinics and providers to join this movement in modernizing women’s healthcare across the globe.

For more information about Tia Clinics using Carevix™, please visit aspivix.com.

About Tia

Funded in 2017 by Carolyn Witte and Felicity Yost, Tia is the modern medical home for women. The company is trailblazing a new paradigm for women’s healthcare that treats women as whole people vs. parts or life stages. Blending in-person and virtual care services, Tia’s “Whole Woman, Whole Life” care model fuses gynecology, primary care, mental health and evidence-based wellness services to treat women comprehensively. By making women’s health higher quality and lower cost, Tia makes women healthier, providers happier, and the business of care delivery stronger — setting a new standard of care for women everywhere. For more information, visit www.asktia.com. Tia, Inc. provides administrative services to Tia Medical Group, P.C and Gynecology Integrative Women’s Care, P.C., which are independently owned by licensed physicians

About Aspivix

Aspivix is a pioneering leader in women’s health, dedicated to modernizing healthcare solutions for women around the world. With a focus on innovation, Aspivix is committed to developing cutting-edge medical devices, such as Carevix™, which aim to transform the gynecological experience by offering safer and less painful solutions that enhance the quality of care and empower women to take control of their health. For more information, visit aspivix.com.

About Carevix™
Carevix™ is an innovative, soft-suction cervical device designed as a modern and gentler alternative to a cervical tenaculum when stabilization of the cervix is needed, aiming to significantly reduce trauma associated with pain and bleeding. Carevix™ received FDA clearance, CE-Mark and MHRA approval, and is available for commercialization in Switzerland, other countries will be available soon.
Carevix™ has been clinically proven to be non-traumatic during transcervical procedures with compelling results from the ADVANCE Women, a multisite randomized controlled trial of Carevix™, used In IUD Procedures against the cervical tenaculum has been published in “Contraception”, the International Reproductive Health Journal in 2023.
Carevix™ has received the Design Award 2022 by the iF DESIGN AWARD, one of the most important and prestigious design awards in the world, amongst other recognitions.

For media inquiries or more information :

Please contact: Ikram Guerd – VP of Global Marketing: ikram.guerd@aspivix.com.

References

1. Michal Yaron, Hélène Legardeur, Bastien Barcellini, Farida Akhoundova, Patrice Mathevet, Safety and efficacy of a suction cervical stabilizer for IUD insertion: results from a randomized, controlled study, Contraception, 2023, 110004, ISSN 0010-7824, Contraception link